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INTRODUCTION
Medullary thyroid carcinoma (m t c ) is a rare cancer 
(less than 8% of all thyroid cancers) that occurs both 
as a familial and as a sporadic disease. Total thyroi-
dectomy with dissection of the ipsilateral and central 
lymph nodes, sometimes extended to contralateral 
dissection, is the primary treatment of hereditary 
and sporadic m t c  alike. after surgery, many patients 
are cured, especially those with familial m t c , who 
are diagnosed early and without metastatic tumour 
spread. However, some patients show persistent dis-
ease after primary surgery, as shown by measurable 
serum calcitonin 1.
Three months after surgery, serum calcitonin 
levels are not detectable in more than 60% of patients 
without lymph node involvement, as compared with 
fewer than 20% of patients with lymph node spread 2. 
For relapses localized in the neck or mediastinum, a 
new surgical resection is usually proposed, but this 
treatment is followed by undetectable levels of serum 
calcitonin in fewer than one third of patients 3. The 
overall survival (o s ) rate 10 years after primary sur-
gery in all patients with m t c  is 69%, which decreases 
to 10% when distant metastases are present 4. Patients 
with localized or metastatic disease may survive for 
some years or may rapidly progress and die. Con-
sequently, highly reliable prognostic indicators are 
needed for the early detection of high-risk patients 
who require treatment as compared with low-risk 
patients who warrant a “watch-and-wait” approach. 
Moreover, these prognostic factors can be very useful 
in the development of new therapeutic modalities.
Here, we consider the most appropriate prognostic 
indicators and the most efficient imaging techniques 
for the selection of patients intended to be treated 
with pretargeted radioimmunotherapy (pr i t ). Then, 
we analyze the effectiveness and toxicity of this new 
therapeutic modality and compare it with alternative 
treatments currently available or in evaluation.
SELECTION OF HIGH-RISK PATIENTS WHO 
NEED TO BE TREATED
advanced age and advanced disease stage, with as-
sociated multiple endocrine neoplasia 2B, are com-
monly accepted factors of poor prognosis in m t c  5. 
Furthermore, the presence of node metastases has 
been reported to be the most significant prognostic 
factor 6. Kebebew et al. 7 stated that the European 
Organization for research and Treatment of Cancer 
prognostic scoring system 8, which takes into account 
age, sex, and nature and stage of the disease, had the 
most effective predictive value.
Mutations in the ret oncogene are frequently 
observed in familial disease and in 43% of sporadic 
cases 9. lower survival rates are associated with these 
mutations. The Cdc25b phosphatase has also been 
presented as a new indicator of aggressive m t c  10. 
However, although these prognostic factors and scor-
ing systems are rather good predictors of probability 
of cure after primary surgery, they are not effective 
in predicting disease outcome for patients who are 
not cured after surgery.
Tumour aggressiveness has been related to the tu-
mour cell proliferation index provided by the measure 
of Ki67 expression, described as another prognostic 
factor 11, and can also be approached by monitoring 
serum calcitonin or carcinoembryonic antigen (c e a ) 
concentration kinetics and by calculating doubling 
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time (d t ). We have shown that calcitonin d t  is an in-
dependent predictor of survival, with a high predictive 
value, in patients with measurable serum calcitonin, 
even after repeated surgery 12. at the end of that study, 
41 patients with a calcitonin d t  greater than 2 years 
were still alive 2.9 years to 29.5 years after their 
initial surgery. deaths from m t c  were recorded in 20 
patients, among whom 8 (67%) with a calcitonin d t  
between 6 months and 2 years died 40–189 months 
after surgery. all 12 patients with a calcitonin d t  be-
low 6 months died of their disease 6 months to 13.3 
years after their initial surgery. Consequently, calci-
tonin d t  was used to select patients with progressive 
disease in two clinical trials of r i t .
The r i t  trials showed a significant increase in o s  
as compared with a historical untreated control group 
matched for calcitonin d t  13. Calcitonin d t  was also 
taken into account in a positron-emission tomography 
(p e t) imaging study that concluded that the maximum 
standard uptake value (s u v max) correlated with cal-
citonin d t , and that combined fluorodeoxyglucose 
(f d g ) p e t–computed tomography (c t ) could be used 
for staging patients with progressive m t c , with pos-
sible prognostication by s u v  quantification 14. The 
s u v max correlated significantly with calcitonin d t  (p = 
0.011) and with minimal d t  (the minimum of c e a and 
calcitonin d t , p = 0.027).
Several imaging methods may be used for patients 
with rapidly progressing metastatic m t c  before any 
treatment: ultrasonography and c t  for neck explora-
tion and c t  for chest, abdomen, and pelvis. Moreover, 
we showed that magnetic resonance imaging (m r i ) 
appears to be a sensitive technique for detecting tu-
mour spread to bone or bone marrow, with a higher 
sensitivity than that for bone scintigraphy 15. We also 
showed that the sensitivity of f d g  p e t–c t  in progres-
sive metastatic m t c  patients was 83% for neck, 85% 
for mediastinum, 75% for lung, 60% for liver, and 
67% for bone metastases, with an overall sensitivity 
of 76%.
PRETARGETED RADIOIMMUNOTHERAPY
For radioresistant solid tumours such as m t c , pretar-
geted r i t  (pr i t ) techniques have been developed to 
increase the therapeutic index over r i t  using directly 
labelled antibodies and to increase the absorbed dose 
delivered to tumour cells 16. an unlabelled antitumour 
immunoconjugate is injected first. Later, when the 
immunoconjugate has cleared sufficiently from the 
circulation, the radionuclide, coupled to a rapidly 
clearing agent with a high affinity for the immunocon-
jugate prelocalized in the tumour, is injected. among 
other alternative techniques, the Affinity Enhance-
ment System uses a bi-specific antibody and a radio-
labelled bivalent hapten. In this system, the affinity 
of the hapten for the bi-specific antibody is limited 
(Kd = 10–8 mol/L), but the bivalent hapten binds avidly 
to the immunoconjugate bound to the surface of target 
cells. The hapten–bi-specific antibody complexes in 
the circulation dissociate and excess hapten is cleared, 
at least in part, through the kidneys.
In a first clinical study, dosimetric results showed 
that small m t c  tumours received potentially tumori-
cidal irradiation (up to 4.7 cGy per megabecquerel), 
a dose comparable to that delivered by 131I therapy 
to metastases of differentiated thyroid carcinoma 
(1.2–3.8 cGy per megabecquerel for tumours of 
8–40 g) 17.
In 1996, a phase i/ii clinical trial then used a mu-
rine bi-specific antibody and a bivalent indium–d t p a  
hapten labelled with 131I to evaluate toxicity, pharma-
cokinetics, dosimetry, and antitumour activity in 26 
patients with recurrence of m t c  18. The dose-limiting 
toxicity was hematologic, and the maximal tolerated 
activity was estimated at 1.8 GBq/m2 in the group of 
patients with suspected bone marrow involvement. 
Some therapeutic responses were observed, mainly 
in patients with a small tumour burden and after re-
peated courses of r i t .
Because of the relatively high hematologic 
toxicity and frequent immune responses, further 
optimization included development of chimeric 
and humanized bi-specific antibodies. To determine 
optimal bi-specific antibody dose, hapten activity, 
and pretargeting interval, a prospective phase i op-
timization study was performed in 34 patients with 
c e a -expressing tumours 19–20. A bi-specific antibody 
dose of 40 mg/m2, with a pretargeting interval of 
5 days, appeared to be a good compromise between 
toxicity and efficacy. Human anti-mouse antibody 
elevation was observed in 8% of patients, and human 
anti-human antibody in 33%.
Six years after the first pr i t  phase i/ii study and 
3 years after the second, long-term disease stabilization 
was observed in 53% of the m t c  patients, as document-
ed by morphologic imaging (c t , m r i ) and serial serum 
calcitonin and c e a  measurements. a retrospective 
study was therefore conducted to compare survival in 
29 patients given pr i t with survival in 39 contempora-
neous untreated patients for whom data were collected 
by the French Tumor Endocrine Group 13. a second 
objective was to examine whether post-pr i t  variation 
in calcitonin d t  could be used as a surrogate marker 
for survival by comparing, among treated patients, the 
survival of biologic responders and non-responders. 
A responder was defined as an individual showing at 
least a 100% increase in calcitonin d t . Overall survival 
was significantly longer in high-risk (calcitonin d t  
< 2 years) treated than in high-risk untreated patients 
(median o s : 110 months vs. 61 months; p < 0.030). 
The 47% of patients defined as biologic respond-
ers experienced significantly longer survival than 
did the non-responders (median o s : 159 months vs. 
109 months; p < 0.035) or untreated patients (median 
o s : 159 months vs. 61 months; p < 0.010). Treated pa-
tients with bone or bone marrow disease had a longer 
survival than did patients without such involvement 5
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(10-year o s : 83% vs. 14%; p < 0.023). Toxicity was 
mainly hematologic and related to bone or bone mar-
row tumour involvement, which was shown by our 
group to be more frequent in patients with metastatic 
m t c  than had been previously reported 15. Indeed, in the 
two phase i/ii studies, m r i  confirmed bone or bone mar-
row involvement in most patients with bone or bone 
marrow activity uptake observed by scintigraphy 13. 
Consequently, the observed hematologic toxicity was 
expected in such patients who had the best response 
rate, probably because their bone marrow involvement 
illustrated the situation of disseminated microscopic 
disease commonly considered as the most favourable 
indication for r i t .
Only 3 cases of myelodysplasia were observed in 
our series of 70 m t c  patients treated with pr i t . These 
3 patients were heavily pretreated, in particular with 
external radiotherapy. No renal toxicity was reported 
after pr i t .
Following the encouraging results obtained in 
the two phase i/ii studies, a phase ii pr i t  study was 
undertaken to evaluate response rate, time to progres-
sion, and o s  in progressive m t c  patients (calcitonin d t  
< 5 years). Between April 2004 and January 2008, 48 
patients were enrolled. So far, 45 patients have been 
treated, receiving 40 mg/m2 of a bi-specific antibody 
(prepared by coupling the Fab fragments of humanized 
anti-c e a  antibody hMN-14 with the Fab fragment of 
the mouse anti-d t p a –indium antibody 734), followed 
by 1.8 GBq/m2 of bivalent indium–d t p a  hapten la-
belled with 131I given 4–6 days later. a second course 
of treatment has been given to 6 of the patients.
a preliminary analysis of the results was performed 
in September 2008 for 33 evaluable patients (20 men, 
13 women) who received 35 treatments and had a me-
dian of 15 months of follow-up (range: 6–36 months). 
a patient was considered unresponsive if progression 
according to the response Evaluation Criteria in Solid 
Tumors (r e c i s t ) criteria, f d g  p e t, or serum concentra-
tion of biomarkers was observed at 3 months post-r i t , 
or if no effect on c e a  or calcitonin d t  (less than 100% 
increase of c e a  or calcitonin d t ) was observed.
In the 33 evaluable patients, the median pre-pr i t  
calcitonin d t  was 1.2 years (range: 0.2–5.9 years), and 
c e a  d t  was 1.8 years (range: 0.5–23.8 years). Tumour 
targeting was shown in all cases. The sensitivity of 
scintigraphic imaging was 92%. Figure 1 shows the 
high tumour uptake observed in a m t c  patient with a 
cardiac metastasis. allergic reactions were observed 
during 2 bi-specific antibody infusions, grade 1 liver 
toxicity after 3 of 35 injections (8.5%), and grade 3 or 
4 hematologic toxicity after 19 of 35 injections (54%). 
Efficacy was observed after 18 of 35 pr i t  injections 
(51%), with a time to progression of 18 months (range: 
6–36 months) by r e c i s t criteria and 15 months (range: 
6–36 months) by p e t and biomarker levels.
In this series, 24% of patients (8/33) were con-
sidered to be low risk (d t  > 2 years), 39% (13/33) 
to be intermediate risk (d t : 6 months–2 years), and 
18% (6/33) to be high risk (d t  < 6 months). Efficacy 
was found in 62% of patients in the low-risk group, 
53% in the intermediate-risk group, and 50% in the 
high-risk group.
ALTERNATIVE TREATMENT MODALITIES
The radiopharmaceutical (90Y–d o t a )–t o c  is another 
agent that has been successfully used in the treatment 
f i g u r e  1  Imaging by (A) fluorodeoxyglucose positron-emission tomography and (B) immunoscintigraphy in a patient having medullary 
thyroid carcinoma with cardiac metastasis. The images show good tumour targeting with both radiopharmaceuticals.6
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of endocrine gastroenteropancreatic tumours, and it 
has been extended to patients with m t c . In a phase ii 
clinical trial, 31 patients with progressive metastatic 
m t c  were injected with a median cumulative activity 
of 12.6 GBq, and response was defined as a decrease 
in serum calcitonin after therapy 21. Interestingly, 
a post-therapeutic prolongation of calcitonin d t  of 
at least 100% 12 was found in 58% of the patients, 
and a significantly longer survival was observed in 
responders than in non-responders. Unfortunately, 
drawing any valid conclusion with regard to a po-
tential survival benefit is difficult because of a lack 
of pre-therapeutic selection of patients based on a 
validated prognostic factor such as calcitonin d t  12. 
Indeed, patients with progressive disease but a long 
calcitonin d t  (>2–5 years), can experience very long 
periods of survival in the absence of treatment. Con-
sequently, it is crucial to select patients with poor 
prognostic indicators before considering a potential 
survival benefit. Moreover, it is important to highlight 
that only 60%–70% of patients with m t c  express so-
matostatin receptors, but more than 90% of patients 
with m t c  express c e a .
Clinical chemotherapy studies—limited in 
number, enrolling small numbers of patients, and 
using various drugs or combinations of drugs—were 
performed more than 10 years ago. In a total of 87 
patients enrolled in four trials and treated with various 
chemotherapeutic regimens, progression-free survival 
(reported for only 22 patients) ranged from 4 months 
to 29 months (median: 10 months). Overall survival 
(reported for 20 patients) ranged from 8.5 months to 
33 months or more (median: 17.5 months) 13. In the 
absence of data on pretreatment prognostic indicators 
of survival for treated patients, it is difficult to draw 
any valid conclusion on the true treatment effective-
ness. Moreover, severe toxicity has been reported 
with some combination chemotherapy regimens 22. 
Consequently, chemotherapy cannot currently be 
considered a promising therapeutic option for patients 
with advanced disease.
In patients with metastases predominantly local-
ized in the liver, selective intra-arterial chemoembo-
lization using various drugs has been performed in 23 
patients in two studies 23,24. Some transient partial re-
mission or stabilization (median duration: 24 months), 
with good symptom palliation, was observed in 70% 
of cases (16/23). This effectiveness was observed 
mainly in patients with limited liver involvement 
(<30%). Thus, chemoembolization can be useful for 
a small percentage of patients with metastatic exten-
sion limited to a small part of the liver. However, in 
our experience, no patient had metastatic extension 
limited to liver 14,15.
among signal transduction pathways that lead 
to neoplastic transformation, the ret protein plays a 
major role in m t c  25. Consequently, ret appears to be 
a favourable target for molecular therapy, even if a 
substantial number of patients with the sporadic form 
of the disease cannot benefit. Other signalling com-
ponents, including receptors for vascular endothe-
lial growth factor (v e g f r ), epidermal growth factor 
(e g f r ), and platelet-derived growth factor (p d g f r ), 
can be involved in m t c , and multikinase inhibitors 
targeting one or some of them have been evaluated 
in clinical trials.
Imatinib mesylate (Gleevec: Novartis Pharma-
ceuticals, St. Louis, MO, U.S.A.), which inhibits Ret 
(among other protein tyrosine kinases) has been used 
in three clinical studies involving 30 patients 26–28. 
Stabilization was observed in 30% of patients (9/30) 
over 6–24 months. Severe toxicity—including rash, 
fatigue, laryngeal mucosal swelling, nausea, and 
vomiting—was reported in one study 27.
More recently, other protein kinase inhibitors 
have been evaluated in patients with advanced m t c , 
and some preliminary results are available in abstract 
form only. axitinib, an inhibitor of v e g f r s 1, 2, and 3, 
was evaluated in 60 patients with advanced thyroid 
cancers, including 12 patients with m t c  29. Stabiliza-
tion was observed in 50% of all patients for up to 
13 months, without any differentiation for patients 
with m t c . Sorafenib, which selectively inhibits ret 
tyrosine kinase, was evaluated in 5 patients with 
metastatic m t c  30. Surprisingly, 1 complete response 
was observed, together with 1 partial response and a 
50% decline of calcitonin in all 5 patients; however, 
the initial dose had to be reduced by 50% because of 
serious side effects. Vandetanib, which targets ret, 
v e g f r , and e g f r  tyrosine kinases, was evaluated in 30 
patients with locally advanced or metastatic heredi-
tary m t c  31. a partial response was observed in 20% 
of patients (6/30) and stabilization in 30% of patients 
(9/30) for up to 9 months. A biologic response was 
observed in 63% (19/30) for at least 6 weeks. Some 
grade 3 adverse events, including rash and diarrhea, 
were observed in 3 patients. Finally, motesanib, which 
targets all known v e g f , p d g f , Kit, and ret receptors, 
was evaluated in 83 patients with both hereditary and 
sporadic m t c  32. a partial response was observed in 2 
patients and stabilization for no longer than 6 months 
in 43 (52%).
PATIENT STRATIFICATION FOR FUTURE 
STUDIES
all these studies performed in patients with advanced 
locally recurrent or metastatic m t c  and using various 
multikinase inhibitors have shown some tumour effect 
documented by a substantial decrease in calcitonin. 
a transient stabilization of disease was observed, 
extending up to more than 24 months. However, in 
the absence of data on real tumour growth rate before 
treatment, it is not possible to draw any valid conclu-
sions about potential survival benefit.
as mentioned earlier, we showed that calcitonin 
d t  is the best prognostic indicator for selecting pa-
tients with rapidly progressing metastatic disease 7
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before any investigational treatment 12. In patients 
with a calcitonin d t  longer than 5 years, life expec-
tancy is very long and watchful waiting may be the 
most appropriate strategy. For patients with a calci-
tonin d t  shorter than 2 years and, all the more, shorter 
than 6 months, the disease is rapidly progressing, 
with a short life expectancy that warrants the use of 
investigational drugs.
CONCLUSIONS
Currently, no drug is approved for the systemic treat-
ment of metastatic m t c . No real survival benefit has 
been convincingly documented with chemotherapy, 
which furthermore is associated with severe toxicity. 
It is too early to evaluate the potential effective-
ness of multikinase inhibitors. reported results of 
phase ii trials have shown some transient disease 
stabilization, but more patients with documented 
rapidly progressive metastatic disease should be 
included and their survival compared with that of 
comparable untreated patients from historical stud-
ies. We appreciate that an optimal comparison would 
use randomized prospective trials, but because of 
the low frequency of m t c , too many years would 
be required to enrol a sufficient number of patients, 
especially if only patients with a short calcitonin d t  
are included. additional years would be necessary 
for survival analyses. To this point, pr i t  has been the 
only innovative treatment modality to convincingly 
show some survival benefit in patients with rapidly 
progressing metastatic disease.
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